BNGO * Stock Overview
Provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Bionano Genomics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$19.50 |
| 52 Week High | US$145.00 |
| 52 Week Low | US$13.00 |
| Beta | 2.41 |
| 1 Month Change | 30.00% |
| 3 Month Change | -1.07% |
| 1 Year Change | -83.19% |
| 3 Year Change | -98.39% |
| 5 Year Change | n/a |
| Change since IPO | -99.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| BNGO * | MX Life Sciences | MX Market | |
|---|---|---|---|
| 7D | -2.5% | 0% | 0% |
| 1Y | -83.2% | 0% | 0% |
Return vs Industry: BNGO * underperformed the MX Life Sciences industry which returned -0.8% over the past year.
Return vs Market: BNGO * underperformed the MX Market which returned 4.5% over the past year.
Price Volatility
| BNGO * volatility | |
|---|---|
| BNGO * Average Weekly Movement | 16.2% |
| Life Sciences Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: BNGO *'s share price has been volatile over the past 3 months.
Volatility Over Time: BNGO *'s weekly volatility (16%) has been stable over the past year, but is still higher than 75% of MX stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 344 | Robert Holmlin | www.bionano.com |
Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics.
Bionano Genomics, Inc. Fundamentals Summary
| BNGO * fundamental statistics | |
|---|---|
| Market cap | Mex$1.17b |
| Earnings (TTM) | -Mex$3.77b |
| Revenue (TTM) | Mex$622.96m |
2.0x
P/S Ratio-0.3x
P/E RatioIs BNGO * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BNGO * income statement (TTM) | |
|---|---|
| Revenue | US$37.47m |
| Cost of Revenue | US$27.15m |
| Gross Profit | US$10.32m |
| Other Expenses | US$237.11m |
| Earnings | -US$226.79m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.39 |
| Gross Margin | 27.54% |
| Net Profit Margin | -605.26% |
| Debt/Equity Ratio | 35.1% |
How did BNGO * perform over the long term?
See historical performance and comparison